| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | Director, 10% Owner
2 companies
Mona Ashiya is Director at STTK and has filed Form 4s across 2 companies. Mona Ashiya's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $20.9M at current prices.
Historically, Mona Ashiya's trades have earned a middling insider score of 66/100 across 14 rated trades. Over a 12-month horizon, 21.4% of those trades were profitable, with an average 12-month return of +5.4%.
The biggest single holding is IRON (~$15.1M) as Director. The IRON filings lean toward selling, a net 747,645 shares.
Mona Ashiya has 18 Form 4 filings on record from December 2022 to July 2026, across 3 companies: Director at VYNE Therapeutics (VYNE), 2026; Director at Shattuck Labs (STTK), 2025–2026; Director at Disc Medicine (IRON), 2022–2025.
The 61 reported transactions were 39 open-market sales, 14 open-market purchases, 7 option or other derivative awards and 1 option exercise.
Counted by filing, the open-market trades come to 3 purchases worth about $11.0M and 6 sales worth about $52.7M.
The largest open-market purchase was 6,306,127 shares of STTK at an average $0.87 on August 25, 2025, about $5.5M. Twelve months later STTK was up 711%.
The largest open-market sale was 433,200 shares of IRON at an average $56.75 on December 14, 2023, about $24.6M. Twelve months later IRON was up 11%.
None of the 6 sales since April 2023 was marked as made under a Rule 10b5-1 trading plan.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Aug 25, 2025 | STTK Shattuck Labs, Inc. | Director | Buy | 6,306,127 | $0.87 | $5,471,826.40 | -120.0% | +107.3% | +711.1% | |
| Mar 24, 2025 | IRON Disc Medicine, Inc. | Director | Sell | 5,738 | $54.11 | $310,483.18 | -3.0% | -3.8% | +11.0% | |
| Mar 21, 2025 | IRON Disc Medicine, Inc. | Director | Sell | 52,429 | $54.02 | $2,831,986.74 | -21.9% | -1.2% | +11.4% | |
| Mar 12, 2025 | IRON Disc Medicine, Inc. | Director | Sell | 312,384 | $54.31 | $16,965,596.07 | -61.7% | -1.6% | +10.8% | |
| Jun 17, 2024 | IRON Disc Medicine, Inc. | Director | Buy | 83,334 | $36.00 | $3,000,024.00 | +54.8% | +6.3% | +11.6% | |
| Dec 18, 2023 | IRON Disc Medicine, Inc. | Director | Sale+OE | 1,724 | $59.24 | $102,129.76 | - | +12.8% | +11.1% | |
| Dec 14, 2023 | IRON Disc Medicine, Inc. | Director | Sell | 433,200 | $56.75 | $24,584,100.00 | -65.9% | +12.4% | +11.4% | |
| Dec 14, 2023 | IRON Disc Medicine, Inc. | Director | Sell | 134,200 | $58.88 | $7,902,266.00 | -15.6% | +12.4% | +11.4% | |
| Feb 15, 2023 | IRON Disc Medicine, Inc. | Director, 10% Owner | Buy | 108,696 | $23.00 | $2,500,008.00 | +57.1% | +40.3% | +177.1% |